ArticleOncology letters2019
Effect of microRNA-27b on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma via FZD7 signaling pathway.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Roles of Wnt ligands and receptors in oral squamous cell carcinoma.Journal of Zhejiang University. Science. B · 2025Review
- β-catenin as a key regulator of the cisplatin response in tumor cells.Clinical and experimental medicine · 2025Review
- Differential Expression of MicroRNA MiR-145 and MiR-155 Downstream Targets in Oral Cancers Exhibiting Limited Chemotherapy Resistance.International journal of molecular sciences · 2024Article
- Chemotherapeutic Drug Resistance Associated with Differential miRNA Expression of miR-375 and miR-27 among Oral Cancer Cell Lines.International journal of molecular sciences · 2023Article
- Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma.Non-coding RNA research · 2022Article
- β-Elemene alleviates cisplatin resistance in oral squamous cell carcinoma cell via inhibiting JAK2/STAT3 pathway in vitro and in vivo.Cancer cell international · 2022Article
- Wnt pathway in oral cancer: A review update.The Saudi dental journal · 2021Review
- Long non-coding RNA OIP5-AS1 contributes to cisplatin resistance of oral squamous cell carcinoma through the miR-27b-3p/TRIM14 axis.Experimental and therapeutic medicine · 2021Article
- Expression and prognostic impact of FZDs in pancreatic adenocarcinoma.BMC gastroenterology · 2021Article
- Integrated miRNA and mRNA Expression Profiles Reveal Differentially Expressed miR-222a as an Antiviral Factor Against Duck Hepatitis A Virus Type 1 Infection.Frontiers in cellular and infection microbiology · 2021Article
- The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma.Frontiers in oncology · 2021Review
- MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.Bioengineered · 2020Article
- LINC01089 Inhibits Tumorigenesis and Epithelial-Mesenchymal Transition of Non-small Cell Lung CancerFrontiers in oncology · 2020Article
Corrections and comments
- Retraction · 2024-04-22Concerns/Issues about Data · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Plagiarism of Data · · See also: https://pubpeer.com/publications/CB3A99887A5E10E411FD9E15929A0A
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effect of microRNA-27b (miR-27b) on cisplatin chemotherapy sensitivity of oral squamous cell carcinoma (OSCC) was investigated to provide a reference for clinical prevention of OSCC cell resistance. The clinical tissues of 34 patients with OSCC-resistant cancer and 28 patients with cisplatin-sensitive OSCC in Nanjing General Hospital were collected. The expression levels of miR-27b and Frizzled-7 (FZD7) in cancer tissues were detected by reverse transcription-quantitative polymerase chain reation (RT-qPCR). After a certain gradient of cisplatin was used to induce stable acquired resistance of OSCC cell line Tca8113/CDDP, a dose of miR-27b was added to construct a cell line overexpressing miR-27b in the drug-resistant cell line. The effect of cisplatin on the proliferation of drug-resistant OSCC cells was detected by colony formation assay. In addition, the scratch test and Transwell formation assay was performed to examine the effect of cisplatin drug stimulation on proliferation and migration of Tca8113/CDDP. Flow cytometry and Hoechst 33258 staining were used to detect the effect of miR-27b on apoptosis of OSCC-resistant cells after cisplatin chemotherapy. The expression level of miR-27b in cancer tissues of patients with drug-resistant OSCC was significantly lower than that of patients with OSCC cisplatin sensitivity (P<0.05). After high expression of miR-27b, the number of clones of drug-resistant OSCC cells after adding cisplatin drugs can be significantly inhibited. The proliferation and migration ability of drug-resistant OSCC was significantly decreased after the addition of cisplatin in miR-27b overexpression (P<0.05). miR-27 mimic enhanced the pro-apoptotic ability of cisplatin drugs (P<0.05). The expression of FZD7 in cisplation-resistant patients was significantly higher (P<0.05). miR-27b significantly inhibited the expression of FZD7 and β-catenin proteins. miR-27b can inhibit the resistance of OSCC to cisplatin drugs, increase apoptosis of cancer cells, and inhibit the proliferation of cancer cells. The mechanism may be related to the inhibition of FZD7/β-catenin signaling pathway activation in drug-resistant cell lines by miR-27b.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.